TARS
Tarsus Pharmaceuticals Inc

885
Mkt Cap
$3.1B
Volume
253,662.00
52W High
$76.81
52W Low
$38.51
PE Ratio
-36.22
TARS Fundamentals
Price
$72.92
Prev Close
$72.53
Open
$71.90
50D MA
$64.34
Beta
0.75
Avg. Volume
593,354.35
EPS (Annual)
-$3.07
P/B
9.24
Rev/Employee
$566,417.96
Loading...
Loading...
News
all
press releases
23,533 Shares in Tarsus Pharmaceuticals, Inc. $TARS Acquired by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight research firms that are covering the stock...
MarketBeat·7h ago
News Placeholder
What is William Blair's Estimate for TARS Q4 Earnings?
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Investment analysts at William Blair lowered their Q4 2025 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a...
MarketBeat·7d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Tarsus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·7d ago
News Placeholder
Q3 Earnings Estimate for TARS Issued By HC Wainwright
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research...
MarketBeat·8d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $87.00 at Guggenheim
Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·9d ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +14.29% and +2.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest TARS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.